The Department of Defense offers the Therapeutic Development Award to support the preclinical assessment of new treatments for Amyotrophic Lateral Sclerosis (ALS). This grant specifically targets empirical and product-driven studies aimed at advancing therapies. While the primary focus is on generating new therapeutic agents and data, proposed research may also incorporate a hypothesis-driven approach, provided the core objective remains centered on the development of therapeutics for ALS. The ultimate goal of this funding is to foster the creation of novel interventions and data that will significantly contribute to the progression of new, effective treatments for individuals suffering from this debilitating disease.
Opportunity ID: 89014
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-11-ALSRP-TDA |
| Funding Opportunity Title: | DoD Amyotrophic Lateral Sclerosis Therapeutic Development Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 2 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Apr 21, 2011 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | Aug 24, 2011 |
| Current Closing Date for Applications: | Aug 24, 2011 |
| Archive Date: | Sep 23, 2011 |
| Estimated Total Program Funding: | $4,800,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: | The Therapeutic Development Award supports the preclinical assessment of therapeutics for ALS. The proposed studies are expected to be empirical in nature and product-driven, but may have a hypothesis-driven approach, provided the focus is on therapeutics. It is anticipated that the agents and/or data generated from these awards will lead to the advancement of new therapies for ALS. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
301-682-5507
Email:help@cdmrp.org |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 89014 Full Announcement-1 -> fy11_alsrp_tda_pa_gg 21 apr.pdf
Packages
| Agency Contact Information: | 301-682-5507 Email: help@cdmrp.org |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 12.420 | PKG00049371 | Apr 21, 2011 | Aug 24, 2011 | View |
Package 1
Mandatory forms
89014 RR_SF424_1_2-1.2.pdf
89014 PerformanceSite_1_4-1.4.pdf
89014 RR_Budget-1.1.pdf
89014 RR_KeyPersonExpanded_1_2-1.2.pdf
Optional forms
89014 RR_SubawardBudget30-1.2.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
